[Adenovirus-mediated p53 gene therapy of human laryngeal cancer].
OBJECTIVE
To explore the potential use of p53 in gene therapy for laryngeal cancer.


METHODS
A human laryngeal cancer cell line Hep-2 was used. Recombinant cytomegalovirus-promoted adeno-viruses containing human wild-type p53 cDNA was transiently introduced into Hep-2 cells in vitro and injected into tumor nodules in vivo. The growth of Hep-2 cells in vitro and established s.c. squamous carcinoma nodules in nude mice was examined.


RESULTS
The transduction efficiency of Hep-2 cell line was 100% at > or = 100 MOI. The p53 protein expression peaked on day 2 after infection and lasted far 5 days. Cell growth was greatly suppressed. In vivo studies, Ad5CMV-p53 transfestion in vitro inhibited tumorigenicity of Hep-2 cells in nude mice. Intra-tumoral injection of Ad5CMV-p53 significantly inhibited established s.c. implanted xenograft.


CONCLUSIONS
Transfection of wild-type p53 gene via Ad5CMV-p53 is a potential approach to the therapy of laryngeal cancer.
Beijing Institute of Otolaryngology.
Q
Q
Wang
D
D
Han
W
W
Wang
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D002455:Cell Division; D005260:Female; D016158:Genes, p53; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D007822:Laryngeal Neoplasms / Q000235:genetics / Q000628:therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D014162:Transfection; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis
D016159:Tumor Suppressor Protein p53